The New American Addiction: How Weight-Loss Drugs Could Create the Next Epidemic

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) have rapidly gained popularity for obesity treatment, with unprecedented public enthusiasm and off-label use in otherwise healthy populations. While these agents demonstrate substantial weight-loss efficacy, emerging concerns highlight potential pharmaceutical dependency, ethical dilemmas, and long-term safety uncertainties. This article critically examines the mechanisms, benefits, and risks of GLP-1 agonists, emphasizing the need for regulatory oversight, psychological safeguards, and integration with lifestyle interventions. We argue for a balanced approach in which pharmacotherapy serves as a temporary adjunct, rather than a substitute, for evidence-based exercise, nutrition, and behavioral strategies essential to sustainable metabolic health.